CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

Approximately 9,000 CVS locations will begin selling Wegovy for $499 per month to customers who pay cash out of pocket.

There could be a new use for semaglutide, the main ingredient of weight loss and diabetes drugs Wegovy and Ozempic. Dr. Jon ...

Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

A latest study has shown promising results in people suffering from metabolic dysfunction-associated steatohepatitis (MASH), ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only ...